Loading
A phase 3 trial of PM8002, Atezolizumab, Etoposide in small-cell lung cancer, run by BioNTech SE, now recruiting.
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer is a phase 3 interventional study registered as NCT06712355 by BioNTech SE, with 621 participants planned, started 2025-02-03 and due to reach its primary completion in 2028-12. Interventions recorded: Pumitamig, Atezolizumab, Etoposide, Carboplatin (or cisplatin if carboplatin is not tolerated). Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares PM8002, BioNTech, Extensive-stage small-cell lung cancer, Etoposide.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Platinum agents, Carboplatin.